Novel paradigms in systemic lupus erythematosus

Lancet, The

393, 2344-2358

DOI: 10.1016/s0140-6736(19)30546-x

Citation Report

#	Article	IF	Citations
1	Effectiveness and cost-effectiveness of a multicomponent intervention to implement a clinical practice guideline for systemic lupus erythematosus: protocol for a cluster-randomized controlled trial. BMC Health Services Research, 2019, 19, 783.	0.9	2
2	Lupus, Silica, and Dietary Omega-3 Fatty Acid Interventions. Toxicologic Pathology, 2019, 47, 1004-1011.	0.9	20
3	Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent. Cells, 2019, 8, 898.	1.8	95
4	01â€...Cytokines in SLE: translational perspectives 2019. , 2019, , .		0
5	04â€...Targeting novel intracellular pathways. , 2019, , .		0
6	01â€...Novel biomarkers for monitoring lupus activity. , 2019, , .		0
7	01â€...We need better classification criteria for lupus. , 2019, , .		0
8	Efficacy of sifalimumab for treatment of skin injury caused by systemic lupus erythematosus. Medicine (United States), 2019, 98, e17607.	0.4	2
9	The role of IL-37 in skin and connective tissue diseases. Biomedicine and Pharmacotherapy, 2020, 122, 109705.	2.5	38
10	Molecular mechanism of celastrol in the treatment of systemic lupus erythematosus based on network pharmacology and molecular docking technology. Life Sciences, 2020, 240, 117063.	2.0	23
11	Tobacco smoking is an independent factor associated with retinal damage in systemic lupus erythematosus: a cross-sectional and retrospective study. Rheumatology International, 2020, 40, 367-374.	1.5	0
12	A Novel Network Pharmacology Strategy to Decode Mechanism of Lang Chuang Wan in Treating Systemic Lupus Erythematosus. Frontiers in Pharmacology, 2020, 11, 512877.	1.6	20
13	Exercise therapy in patients with idiopathic inflammatory myopathies and systemic lupus erythematosus â€“ A systematic literature review. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101547.	1.4	26
14	Bacteroides fragilis alleviates the symptoms of lupus nephritis via regulating CD1d and CD86 expressions in B cells. European Journal of Pharmacology, 2020, 884, 173421.	1.7	16
15	Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus. International Immunopharmacology, 2020, 89, 107028.	1.7	17
16	Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology, 2020, 59, v29-v38.	0.9	80
17	Systemic Lupus Erythematosus: Considerations in Diagnosis and Management for the Inpatient Dermatologist. Current Dermatology Reports, 2020, 9, 220-230.	1.1	0
18	09â€...Novel intracellular pathways. , 2020, , .		0

#	Article	IF	Citations
19	Janus Kinase Inhibition and SLE: Is this a Plausible Treatment Option for SLE?. Current Treatment Options in Rheumatology, 2020, 6, 406-417.	0.6	3
20	10â€...Molecules in early development. , 2020, , .		0
21	08â€...IL-12/23 directed therapies in SLE. , 2020, , .		0
22	Systemic lupus erythematosus: year in review 2019. Chinese Medical Journal, 2020, 133, 2189-2196.	0.9	20
23	Tripterygium and its plant extraction for systemic lupus erythematosus. Medicine (United States), 2020, 99, e21909.	0.4	4
24	Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview. Biomedicines, 2020, 8, 303.	1.4	2
25	HLA-G Expressing Immune Cells in Immune Mediated Diseases. Frontiers in Immunology, 2020, 11, 1613.	2.2	36
26	Differential approach to peripheral blood cell ratios in patients with systemic lupus erythematosus and various manifestations. Rheumatology International, 2020, 40, 1625-1629.	1.5	10
27	T Cells in Autoimmunity-Associated Cardiovascular Diseases. Frontiers in Immunology, 2020, 11, 588776.	2.2	24
28	Autoimmunity and organ damage in systemic lupus erythematosus. Nature Immunology, 2020, 21, 605-614.	7.0	294
29	Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility. Rheumatology, 2020, 59, 3435-3442.	0.9	23
30	Uric acid and kidney damage in systemic lupus erythematosus. Clinica Chimica Acta, 2020, 508, 197-205.	0.5	17
31	Naringenin mitigates autoimmune features in lupus-prone mice by modulation of T-cell subsets and cytokines profile. PLoS ONE, 2020, 15, e0233138.	1.1	9
32	Impact of COVID-19 pandemic on SLE: beyond the risk of infection. Lupus Science and Medicine, 2020, 7, e000408.	1.1	22
33	MicroRNAs in Systemic Lupus Erythematosus: a Perspective on the Path from Biological Discoveries to Clinical Practice. Current Rheumatology Reports, 2020, 22, 17.	2.1	20
34	Clinical and histopathological features and short-term outcomes of lupus nephritis: a prospective study of 100 Egyptian patients. Lupus, 2020, 29, 993-1001.	0.8	5
35	Hypertension and vascular alterations in lupus autoimmunity. Journal of Hypertension, 2020, 38, 1257-1258.	0.3	1
36	Livedo racemosa in neurological diseases: an update on the differential diagnoses. European Journal of Neurology, 2020, 27, 1832-1843.	1.7	6

#	Article	IF	Citations
37	Biosimilars. Lupus, 2020, 29, 525-532.	0.8	3
38	The pathogenic role of innate lymphoid cells in autoimmune-related and inflammatory skin diseases. Cellular and Molecular Immunology, 2020, 17, 335-346.	4.8	23
39	Peptide-Based Vaccination Therapy for Rheumatic Diseases. Journal of Immunology Research, 2020, 2020, 1-15.	0.9	6
41	Association of FcÎ³RIIAâ€R/H131 polymorphism and systemic lupus erythematosus lupus nephritis risk: A metaâ€analysis. International Journal of Rheumatic Diseases, 2020, 23, 853-867.	0.9	0
42	JAK Inhibitors: Prospects in Connective Tissue Diseases. Clinical Reviews in Allergy and Immunology, 2020, 59, 334-351.	2.9	83
43	Autophagy as a modulator of cell death machinery. Cell Death and Disease, 2020, 11, 517.	2.7	124
44	Wire-loop lesion is associated with serological immune abnormality, but not renal prognosis, in lupus nephritis. Lupus, 2020, 29, 407-412.	0.8	2
45	T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nature Reviews Rheumatology, 2020, 16, 100-112.	3.5	174
46	Double Negative B Cell Is Associated With Renal Impairment in Systemic Lupus Erythematosus and Acts as a Marker for Nephritis Remission. Frontiers in Medicine, 2020, 7, 85.	1.2	31
48	Serum GlycA Level Is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity. Journal of Clinical Medicine, 2020, 9, 970.	1.0	8
49	Update on Lupus Nephritis: Looking for a New Vision. Nephron, 2021, 145, 1-13.	0.9	49
50	Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review. Clinical Reviews in Allergy and Immunology, 2021, 60, 17-30.	2.9	15
51	Harnessing SLE Autoantibodies for Intracellular Delivery of Biologic Therapeutics. Trends in Biotechnology, 2021, 39, 298-310.	4.9	16
52	Palmoplantar lichen planusâ€like lupus erythematosus keratoderma: an underrecognized and distinctive cutaneous manifestation of systemic or subacute lupus erythematosus. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e124-e126.	1.3	1
53	Plasmacytoid dendritic cells in the eye. Progress in Retinal and Eye Research, 2021, 80, 100877.	7.3	33
54	Co-occurring Wilsonâ€™s disease and non-penicillamine-induced systematic lupus erythematosus: a case report and literature review. Clinical Rheumatology, 2021, 40, 2485-2490.	1.0	4
55	What is the value of repeat kidney biopsies in patients with lupus nephritis?. Lupus, 2021, 30, 25-34.	0.8	9
56	Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nature Reviews Rheumatology, 2021, 17, 98-108.	3.5	143

#	Article	IF	Citations
57	Quantitative proteomics of epigenetic histone modifications in MCF-7 cells under estradiol stimulation. Analytical Methods, 2021, 13, 469-476.	1.3	0
58	Analysis of time course and dose effect of tacrolimus on proteinuria in lupus nephritis patients. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 106-113.	0.7	7
59	Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Modern Rheumatology, 2021, 31, 1-12.	0.9	52
60	Lupus low disease activity (SLE) in patients treated with belimumab: a single-center real-life experience (2016â€“2019). Clinical Rheumatology, 2021, 40, 923-927.	1.0	5
61	The role of vitamin D in autoimmune diseases: could sex make the difference?. Biology of Sex Differences, 2021, 12, 12.	1.8	53
62	Precision medicine in autoimmune disease. , 2021, , 169-187.		0
63	Interleukin-22 and connective tissue diseases: emerging role in pathogenesis and therapy. Cell and Bioscience, 2021, 11, 2.	2.1	14
65	Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review. BioDrugs, 2021, 35, 175-186.	2.2	2
66	Downregulated Serum Exosomal miR-451a Expression Correlates With Renal Damage and Its Intercellular Communication Role in Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 630112.	2.2	24
67	Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis. Lupus Science and Medicine, 2021, 8, e000458.	1.1	8
68	Interferon Î± Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 498703.	2.2	23
69	Extracellular Vesicles and Immune System in Ageing and Immune Diseases. Experimental Neurobiology, 2021, 30, 32-47.	0.7	3
70	Genetically Predicted Serum Iron Status Is Associated with Altered Risk of Systemic Lupus Erythematosus among European Populations. Journal of Nutrition, 2021, 151, 1473-1478.	1.3	7
71	Abnormal thymic B cell activation and impaired T cell differentiation in pristane-induced lupus mice. Immunology Letters, 2021, 231, 49-60.	1.1	5
72	COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions. RMD Open, 2021, 7, e001638.	1.8	9
73	Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus. Rheumatology, 2021, , .	0.9	1
74	Generation of Systemic Lupus Erythematosus Patient-Derived Induced Pluripotent Stem Cells from Blood. Stem Cells and Development, 2021, 30, 227-233.	1.1	3
75	Association of LncRNAâ€GAS5 gene polymorphisms and PBMC LncRNAâ€GAS5 level with risk of systemic lupus erythematosus in Chinese population. Journal of Cellular and Molecular Medicine, 2021, 25, 3548-3559.	1.6	15

#	Article	IF	Citations
76	EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice. Frontiers in Immunology, 2021, 12, 653989.	2.2	17
77	Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention. Inflammation, 2021, 44, 1663-1682.	1.7	21
78	HDAC1 potentiates CD4Â+ÂT cell activation by inhibiting miR-124 and promoting IRF1 in systemic lupus erythematosus. Cellular Immunology, 2021, 362, 104284.	1.4	8
79	Role of Proteasomes in Inflammation. Journal of Clinical Medicine, 2021, 10, 1783.	1.0	43
81	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.4	39
82	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. Journal of Clinical Medicine, 2021, 10, 1690.	1.0	10
83	Toll-Like Receptors Gene Polymorphisms in Autoimmune Disease. Frontiers in Immunology, 2021, 12, 672346.	2.2	34
84	A molecular signature as a guidance for glucocorticoid: are we there yet?. Lancet Rheumatology, The, 2021, 3, e315-e317.	2.2	1
85	Granulocyte colonyâ€stimulating factor is not pathogenic in lupus nephritis. Immunity, Inflammation and Disease, 2021, 9, 758-770.	1.3	6
86	Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development. Pharmaceuticals, 2021, 14, 525.	1.7	10
87	Overview of therapeutic applications of non-invasive vagus nerve stimulation: a motivation for novel treatments for systemic lupus erythematosus. Bioelectronic Medicine, 2021, 7, 8.	1.0	13
88	Understanding the impact of systemic lupus erythematosus on work amongst South Asian people in the UK: An explorative qualitative study. Lupus, 2021, 30, 1492-1501.	0.8	3
89	Maternal Systemic Lupus Erythematosus (SLE) High Risk for Preterm Delivery and Not for Long-Term Neurological Morbidity of the Offspring. Journal of Clinical Medicine, 2021, 10, 2952.	1.0	8
90	Lupus Cohorts. Rheumatic Disease Clinics of North America, 2021, 47, 457-479.	0.8	1
91	SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis. IScience, 2021, 24, 102510.	1.9	5
92	Novel Long Non-coding RNA Expression Profile of Peripheral Blood Mononuclear Cells Reveals Potential Biomarkers and Regulatory Mechanisms in Systemic Lupus Erythematosus. Frontiers in Cell and Developmental Biology, 2021, 9, 639321.	1.8	12
93	Emerging roles of circular RNAs in systemic lupus erythematosus. Molecular Therapy - Nucleic Acids, 2021, 24, 212-222.	2.3	23
94	Suitability for e-health of non-pharmacological interventions in connective tissue diseases: scoping review with a descriptive analysis. RMD Open, 2021, 7, e001710.	1.8	6

#	Article	IF	Citations
96	Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor. Frontiers in Immunology, 2021, 12, 675542.	2.2	18
97	Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells. Nature Biomedical Engineering, 2021, 5, 968-982.	11.6	52
98	Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials. Chinese Journal of Integrative Medicine, 2021, 27, 778-787.	0.7	10
99	The emerging roles of exosomes in autoimmune diseases, with special emphasis on microRNAs in exosomes. Pharmacological Research, 2021, 169, 105680.	3.1	33
100	Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune Pancreatitis and IgG4-Related Disease. Frontiers in Immunology, 2021, 12, 713779.	2.2	6
101	Oral corticosteroid dosage and clinical presentation of psychiatric conditions after steroid use: A consultationâ€liaison psychiatry serviceâ€™s experience. Neuropsychopharmacology Reports, 2021, , .	1.1	5
102	Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses. EBioMedicine, 2021, 70, 103477.	2.7	29
103	Systemic lupus erythematosus: a clinical update. Internal Medicine Journal, 2021, 51, 1219-1228.	0.5	2
104	Predicting lupus low disease activity state and remission in SLE: novel insights. Expert Review of Clinical Immunology, 2021, 17, 1083-1089.	1.3	3
105	The Interleukinâ€1 Receptorâ€“Associated Kinase 4 Inhibitor PFâ€06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial. Arthritis and Rheumatology, 2021, 73, 2206-2218.	2.9	39
106	Immunological Involvement of MicroRNAs in the Key Events of Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 699684.	2.2	19
107	Remission after Six Months of Induction Immunosuppressive Treatment with Mycofenolate Mofetil and Prednisolone in Patients with Lupus Nephritis: A Descriptive Cross-sectional Study. Journal of the Nepal Medical Association, 2021, 59, 791-794.	0.1	0
108	Role of NLRP3 Inflammasome in Lupus Nephritis and Therapeutic Targeting by Phytochemicals. Frontiers in Pharmacology, 2021, 12, 621300.	1.6	9
109	Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus. Current Opinion in Rheumatology, 2021, 33, 592-597.	2.0	9
110	Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases. Autoimmunity Reviews, 2022, 21, 102931.	2.5	7
111	Integrative Therapy Combining Chinese Herbal Medicines With Conventional Treatment Reduces the Risk of Cardiovascular Disease Among Patients With Systemic Lupus Erythematosus: A Retrospective Population-Based Cohort Study. Frontiers in Pharmacology, 2021, 12, 737105.	1.6	6
112	The role of Bruton's tyrosine kinase in the immune system and disease. Immunology, 2021, 164, 722-736.	2.0	41
113	Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open, 2021, 7, e001747.	1.8	10

#	Article	IF	Citations
114	The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases. Frontiers in Pharmacology, 2021, 12, 732790.	1.6	15
115	Prognostic Impact of Genetic Variants of MECP2 and TIRAP on Clinical Outcomes of Systemic Lupus Erythematosus with and without Nephritis. Biomolecules, 2021, 11, 1378.	1.8	2
116	TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy, 2021, 13, 1135-1150.	1.0	23
117	Nontargeted serum metabolomics analysis and potential biomarkers for systemic lupus erythematosus. Microchemical Journal, 2021, 170, 106677.	2.3	2
118	Intestinal Dysbiosis in Autoimmune Diseases. , 2022, , .		0
119	Effect of interleukin-6, -17, -21, -22, and -23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis. Immunologic Research, 2021, 69, 26-42.	1.3	18
120	Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis. Journal of Translational Medicine, 2021, 19, 35.	1.8	96
121	A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. F1000Research, 2020, 9, 905.	0.8	16
122	PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. Nauchno-Prakticheskaya Revmatologiya, 0, 57, 1-40.	0.2	23
123	Systemic lupus erythematosus: new horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 5-14.	0.2	16
124	Clinical and laboratory relationships in patients with different variants of the course of systemic lupus erythematosus. Sovremennaya Revmatologiya, 2020, 14, 26-31.	0.1	2
125	Neonatal Fc receptor expression in lymphoid and myeloid cells in systemic lupus erythematosus. Lupus, 2021, 30, 1938-1945.	0.8	4
126	Adult-onset Stillâ€™s disease with multiple lymphadenopathy: a case report and literature review. Diagnostic Pathology, 2021, 16, 97.	0.9	2
127	Prevalence, clinical features, risk factors, and outcomes of SLE patients with aortic aneurysm: a cross-sectional retrospective study in a Chinese single center. Clinical Rheumatology, 2021, , 1.	1.0	3
128	Ankle-Brachial Index in Systemic Lupus Erythematosus: A Senegalese Case-Control Study. World Journal of Cardiovascular Diseases, 2019, 09, 958-968.	0.0	0
129	Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. Mediterranean Journal of Rheumatology, 2019, 31, 87.	0.3	2
130	Treatment of Systemic Lupus Erythematosus. Korean Journal of Medicine, 2020, 95, 162-169.	0.1	2
132	New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 537-546.	0.2	7

#	Article	IF	Citations
133	Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis. Current Pharmaceutical Design, 2020, 26, 5998-6006.	0.9	2
134	Maternal Mortality and Morbidity in Autoimmune Diseases. , 2020, , 197-202.		0
135	Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus. Sovremennaya Revmatologiya, 2020, 14, 6-11.	0.1	2
136	Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 428-436.	0.2	1
137	Investigation of the effect of Huaiqihuang granules via adjuvant treatment in children with relapsed systemic lupus erythematosus. American Journal of Translational Research (discontinued), 2021, 13, 3222-3229.	0.0	0
138	Expression of lncRNA NEAT1 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and its correlation with Th1/Th2 balance. International Journal of Clinical and Experimental Pathology, 2021, 14, 646-652.	0.5	5
139	Expression gÃ©nitale des maladies systÃ©miques. , 2021, , 305-319.		0
140	Association Between the Interferon-Î³ +874 T/A Polymorphism and the Risk and Clinical Manifestations of Systemic Lupus Erythematosus: A Preliminary Study. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1475-1482.	0.4	4
141	B cell-activating factor and its targeted therapy in autoimmune diseases. Cytokine and Growth Factor Reviews, 2022, 64, 57-70.	3.2	16
142	Helicobacter pylori and its association with autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis and SjÃ¶gren syndrome. Journal of Translational Autoimmunity, 2021, 4, 100135.	2.0	7
143	PET Imaging in Rheumatic Diseases. , 2021, , .		0
144	Hydroxychloroquine versus tacrolimus for the treatment of persistently active systemic lupus erythematosus. Modern Rheumatology, 2022, 32, 345-350.	0.9	2
145	Pulmonary thromboembolism and alveolar hemorrhage as initial manifestations of systemic lupus erythematosus. Lupus, 2022, 31, 116-124.	0.8	2
146	High Interferon Signature Leads to Increased STAT1/3/5 Phosphorylation in PBMCs From SLE Patients by Single Cell Mass Cytometry. Frontiers in Immunology, 2022, 13, 833636.	2.2	5
147	Systemic lupus erythematosus simultaneously presenting with visceral muscle dysmotility syndrome and mechanical intestinal obstruction clinically relieved by surgery: a case report and literature review. BMC Gastroenterology, 2022, 22, 32.	0.8	2
148	Dysbiosis and probiotic applications in autoimmune diseases. , 2022, , 269-294.		0
149	Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis. Arthritis Research and Therapy, 2022, 24, 6.	1.6	3
151	First Presentation of Systemic Lupus Erythematosus in a 24-Year-Old Male following mRNA COVID-19 Vaccine. Case Reports in Rheumatology, 2022, 2022, 1-4.	0.2	10

#	Article	IF	Citations
152	The small heat shock protein HSPB5 attenuates the severity of lupus nephritis in lupus-prone mice. Autoimmunity, 2022, , 1-11.	1.2	2
153	A Study of IFN-Î±-Induced Chemokines CCL2, CXCL10 and CCL19 in Patients with Systemic Lupus Erythematosu. Life, 2022, 12, 251.	1.1	3
154	N6-methyladenosine-dependent modification of circGARS acts as a new player that promotes SLE progression through the NF-Îº B/A20 axis. Arthritis Research and Therapy, 2022, 24, 37.	1.6	13
155	Physical Activity and Systemic Lupus Erythematosus Among European Populations: A Two-Sample Mendelian Randomization Study. Frontiers in Genetics, 2021, 12, 784922.	1.1	5
156	Exploration of Potential Integrated Models of N6-Methyladenosine Immunity in Systemic Lupus Erythematosus by Bioinformatic Analyses. Frontiers in Immunology, 2021, 12, 752736.	2.2	11
158	Lifestyle Interventions and Weight Management in Systemic Lupus Erythematosus Patients: A Systematic Literature Review and Metanalysis. Journal of Lifestyle Medicine, 2022, 12, 37-46.	0.3	4
159	Neuronal NR4A1 deficiency drives complement-coordinated synaptic stripping by microglia in a mouse model of lupus. Signal Transduction and Targeted Therapy, 2022, 7, 50.	7.1	19
160	Study on the Relationship between lncRNA Gene Polymorphism and Systemic Lupus Erythematosus. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-7.	0.7	3
161	Insights Gained and Future Outlook From scRNAseq Studies in Autoimmune Rheumatic Diseases. Frontiers in Immunology, 2022, 13, 849050.	2.2	2
162	X-Chromosome Inactivation and Related Diseases. Genetical Research, 2022, 2022, 1-8.	0.3	15
163	Discovery of Novel Circulating Immune Complexes in Lupus Nephritis Using Immunoproteomics. Frontiers in Immunology, 2022, 13, 850015.	2.2	6
164	Lower socioeconomic status worsens outcome of patients with systemic lupus erythematosus independently of access to healthcare. Lupus, 2022, 31, 532-540.	0.8	8
165	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases, 2022, 81, 951-961.	0.5	38
166	Involvement of IL-33 in the Pathophysiology of Systemic Lupus Erythematosus: Review. International Journal of Molecular Sciences, 2022, 23, 3138.	1.8	7
167	Research progress of BK virus and systemic lupus erythematosus. Lupus, 2022, 31, 522-531.	0.8	1
168	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Rheumatology and Therapy, 2022, 9, 781-802.	1.1	9
169	Pr-AKI: Acute Kidney Injury in Pregnancy â€“ Etiology, Diagnostic Workup, Management. Geburtshilfe Und Frauenheilkunde, 2022, 82, 297-316.	0.8	1
170	Serum Cytokine Levels of Systemic Lupus Erythematosus Patients in the Presence of Concomitant Cardiovascular Diseases. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 852-861.	0.6	5

#	Article	IF	Citations
171	AMG853, A Bispecific Prostaglandin D2 Receptor 1 and 2 Antagonist, Dampens Basophil Activation and Related Lupus-Like Nephritis Activity in Lyn-Deficient Mice. Frontiers in Immunology, 2022, 13, 824686.	2.2	3
172	White Matter Hyperintensities as a Risk Factor for Ischemic Stroke in Patients With Systemic Lupus Erythematosus. Frontiers in Neurology, 2021, 12, 738173.	1.1	2
173	Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus. RMD Open, 2021, 7, e002010.	1.8	8
174	Analyzing systemic lupus erythematosus publications using neural networkâ€“based multi-label classification algorithms. Lupus, 2022, 31, 820-827.	0.8	1
178	MiR-145 participates in the development of lupus nephritis by targeting CSF1 to regulate the JAK/STAT signaling pathway. Cytokine, 2022, 154, 155877.	1.4	6
179	Identification of oral immune disordersâ€“ A review and a diagnostic algorithm. Disease-a-Month, 2022, , 101350.	0.4	0
180	Identification and functional analysis of a novel phospholipase D2 gene mutation associated with familial systemic lupus erythematosus. Journal of Central South University (Medical Sciences), 2021, 46, 234-239.	0.1	1
181	LangChuangHeJi decoction ameliorates lupus via preventing accumulation of CD138+ T cells in MRL/lpr mice.. American Journal of Translational Research (discontinued), 2021, 13, 12440-12460.	0.0	0
182	DNMT3B (rs2424913) polymorphism is associated with systemic lupus erythematosus alone and with co-existing periodontitis in a Brazilian population. Journal of Applied Oral Science, 2022, 30, e20210567.	0.7	2
183	Potential Small Molecules for Therapy of Lupus Nephritis Based on Genetic Effect and Immune Infiltration. BioMed Research International, 2022, 2022, 1-16.	0.9	12
184	Polymorphism in STAT4 Increase the Risk of Systemic Lupus Erythematosus: An Updated Meta-Analysis. International Journal of Rheumatology, 2022, 2022, 1-8.	0.9	2
185	Serum cytokines to predict systemic lupus erythematosus clinical and serological activity. Clinical and Translational Science, 2022, 15, 1676-1686.	1.5	5
186	Glucocorticoid prevents CD138 expression in TÂcells of autoimmune MRL/lpr mice. Molecular Medicine Reports, 2022, 25, .	1.1	0
187	The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nature Reviews Immunology, 2023, 23, 9-23.	10.6	99
188	Novel loss-of-function mutations in TNFAIP3 gene in patients with lupus nephritis. CKJ: Clinical Kidney Journal, 2022, 15, 2027-2038.	1.4	9
189	Identification of Diagnostic Gene Markers and Immune Infiltration in Systemic Lupus. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-21.	0.7	3
190	Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus. Biomaterials, 2022, 285, 121517.	5.7	23
191	A ceRNA regulatory network in systemic lupus erythematosus and its molecular interplay with cancer. Annals of Translational Medicine, 2022, 10, 563-563.	0.7	2

#	Article	IF	Citations
192	Neuropsychiatric Systemic Lupus Erythematosus: A Remaining Challenge. Current Pharmaceutical Design, 2022, 28, 881-891.	0.9	4
193	Different roles of urinary light chains and serum light chains as potential biomarkers for monitoring disease activity in systemic lupus erythematosus. PeerJ, 0, 10, e13385.	0.9	5
194	Impaired left ventricular systolic synchrony in patients with lupus Nephritis: A speckle tracking echocardiography study. Lupus, 2022, , 096120332211027.	0.8	1
195	Comparative efficacy and safety of mizoribine and mycophenolate mofetil for treating systemic lupus erythematosus: a retrospective cohort study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210963.	1.2	1
196	Risk factors for 1-year hospital readmissions in patients with systemic lupus erythematosus. Clinical and Experimental Medicine, 0, , .	1.9	0
197	â€œListen to Your Immune System When Itâ€™s Calling for Youâ€: Monitoring Autoimmune Diseases Using the iShU App. Sensors, 2022, 22, 3834.	2.1	1
198	An Unusual Case of Kidney Injury in a Young Woman with a Connective Tissue Disease. Case Reports in Nephrology, 2022, 2022, 1-4.	0.2	0
199	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 1420-1427.	0.5	24
200	Association between genetic variants of <scp>microRNA</scp>â€21 and <scp>microRNA</scp>â€155 and systemic lupus erythematosus: A caseâ€control study from a Chinese population. Journal of Clinical Laboratory Analysis, 2022, 36, .	0.9	6
201	Management practice and treatment outcomes of adult patients with Lupus Nephritis at the Renal Clinic of St. Paulâ€™s Hospital Millennium Medical College, Addis Ababa, Ethiopia. BMC Nephrology, 2022, 23, .	0.8	2
202	Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis. , 2022, 1, 32.		0
203	The Role of T Helper 22 Cells in Dermatological Disorders. Frontiers in Immunology, 0, 13, .	2.2	8
204	2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus. Biomedicines, 2022, 10, 1675.	1.4	0
205	Recommendations for Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2022, 48, 617-636.	0.8	8
206	Exploration of the molecular mechanisms, shared gene signatures, and MicroRNAs between systemic lupus erythematosus and diffuse large B cell lymphoma by bioinformatics analysis. Lupus, 2022, 31, 1317-1327.	0.8	3
207	TMT-based quantitative proteomics analysis and potential serum protein biomarkers for systemic lupus erythematosus. Clinica Chimica Acta, 2022, 534, 43-49.	0.5	5
208	The enigma of mixed connective tissue diseaseâ€”challenges in routine care. Clinical Rheumatology, 2022, 41, 3503-3511.	1.0	3
209	Recent Advances in SLE Treatment Including Biologic Therapies. , 0, , .		0

#	Article	IF	Citations
210	Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. New England Journal of Medicine, 2022, 387, 321-331.	13.9	47
211	Safety and Efficacy of Switching Immunosuppressive Drugs for Maintenance Treatment in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study. Modern Rheumatology, 0, , .	0.9	0
212	Pathological mechanisms and crosstalk among different forms of cell death in systemic lupus erythematosus. Journal of Autoimmunity, 2022, 132, 102890.	3.0	10
213	Identifying key genes in CD4+ T cells of systemic lupus erythematosus by integrated bioinformatics analysis. Frontiers in Genetics, 0, 13, .	1.1	4
214	Systemic lupus erythematosus and cardiovascular disease. Journal of Internal Medicine, 2023, 293, 48-62.	2.7	17
215	Systematic lupus erythematous patients following COVID-19 vaccination: Its flares up and precautions. Annals of Medicine and Surgery, 2022, 80, .	0.5	6
216	Anti-Non-Bilayer Phospholipid Arrangement Antibodies Trigger an Autoimmune Disease Similar to Systemic Lupus Erythematosus in Mice. , 0, , .		0
217	The anti-inflammatory effects of Hedyotis diffusa Willd on SLE with STAT3 as a key target. Journal of Ethnopharmacology, 2022, 298, 115597.	2.0	6
218	Systemic lupus erythematosus: history and modernity. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 397-412.	0.2	11
219	Insulin Resistance and Diabetes Mellitus in Patients with Systemic Lupus Erythematosus. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2023, 23, 503-514.	0.6	3
220	An artificial neural network model based on autophagy-related genes in childhood systemic lupus erythematosus. Hereditas, 2022, 159, .	0.5	0
221	lncRNA Xâ€inactiveâ€specific transcript is a potential biomarker related to changes in CD4 ⁺ T cell levels in systemic lupus erythematosus. Rheumatology & Autoimmunity, 2022, 2, 159-174.	0.3	0
222	Distinct binding mode of BAFF antagonist antibodies belimumab and tabalumab, analyzed by computer simulation. Journal of Molecular Modeling, 2022, 28, .	0.8	0
223	Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. New England Journal of Medicine, 2022, 387, 894-904.	13.9	37
224	Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia. Arthritis Research and Therapy, 2022, 24, .	1.6	9
225	Oral Manifestations of Systemic Lupus Erythematosus: A Systematic Review. International Journal of Environmental Research and Public Health, 2022, 19, 11910.	1.2	7
226	New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review. Rheumatology International, 2022, 42, 2261-2266.	1.5	14
228	New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies. Journal of Allergy and Clinical Immunology, 2022, 150, 1289-1301.	1.5	10

#	Article	IF	Citations
229	Predictors of pain catastrophizing in women with systemic lupus erythematosus. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2022, 68, 1247-1251.	0.3	0
230	Novel and emerging treatment strategies for lupus nephritis. Expert Review of Clinical Pharmacology, 2022, 15, 1283-1292.	1.3	5
231	Clinical and immunological phenotypes of systemic lupus erythematosus, identified based on cluster analysis of data from 400 patients from V.A. Nasonova Research Institute of Rheumatology. Sovremennaya Revmatologiya, 2022, 16, 13-21.	0.1	4
232	High mobility group box protein 1 (HMGB1) serum and urinary levels and gene polymorphism in Egyptian patients with systemic lupus erythematosus: A possible relation to lupus nephritis. Lupus, 0, , 096120332211324.	0.8	1
235	Long-term opioid therapy among patients with systemic lupus erythematosus in the community. A Lupus Midwest Network study. Journal of Rheumatology, 0, , jrheum.220822.	1.0	1
236	Experimental spectroscopy, eco-friendly solvents effect on transitions, reactive sites and biological research on methyl gallate â€“ MTT assay (cytotoxicity). Journal of Molecular Liquids, 2023, 371, 121092.	2.3	4
237	Balneotherapy, a Complementary Non-pharmacological Approach for Non-Inflammatory Complaints in Systemic Lupus Erythematosus: A Pilot Study. In Vivo, 2022, 36, 3010-3017.	0.6	2
238	Assessing Myocardial Involvement in Systemic Lupus Erythematosus Patients without Cardiovascular Symptoms by Technetium-99m-sestamibi Myocardial Perfusion Imaging: A Correlation Study on NT-proBNP. Current Medical Imaging, 2022, 19, .	0.4	0
239	Omega-3 fatty acids: Current insights into mechanisms of action in systemic lupus erythematosus. Lupus, 2023, 32, 7-22.	0.8	3
240	Psychological Implications to the Therapy of Systemic Lupus Erythematosus. International Journal of Environmental Research and Public Health, 2022, 19, 16021.	1.2	0
241	HSPB5 suppresses renal inflammation and protects lupus-prone NZB/W F1 mice from severe renal damage. Arthritis Research and Therapy, 2022, 24, .	1.6	1
242	Nutritional, biochemical, and clinical determinants of hyperuricemia in systemic lupus erythematosus patients: Relationship with clinical and renal disease activity. Lupus, 0, , 096120332211469.	0.8	0
243	Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus. Rheumatology and Therapy, 2023, 10, 7-34.	1.1	8
244	Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis. Lupus, 2023, 32, 325-341.	0.8	9
245	Mitochondrial DNA: a novel indicator of active inflammation in ANCA-associated vasculitides. Rheumatology, 0, , .	0.9	0
246	RBPâ€“RNA interactions in the control of autoimmunity and autoinflammation. Cell Research, 2023, 33, 97-115.	5.7	18
247	Sex-Specific Outcomes of Acute Stroke in Patients with Systemic Lupus Erythematosus: A National Inpatient Sample Study. Journal of Clinical Medicine, 2023, 12, 462.	1.0	0
248	Accumulation of Fat Not Responsible for Femoral Head Necrosis, Revealed by Single-Cell RNA Sequencing: A Preliminary Study. Biomolecules, 2023, 13, 171.	1.8	1

#	Article	IF	Citations
249	The Association between Blood Lipids and Systemic Lupus Erythematosus: A Two-Sample Mendelian Randomization Research. Metabolites, 2023, 13, 27.	1.3	2
250	Amelioration of Autoimmunity in a Lupus Mouse Model by Modulation of <scp>Tâ€Bet</scp>â€“Promoted Energy Metabolism in Pathogenic Age/<scp>Autoimmuneâ€Associated</scp> B Cells. Arthritis and Rheumatology, 2023, 75, 1203-1215.	2.9	7
251	Circular RNA in autoimmune diseases: special emphasis on regulation mechanism in RA and SLE. Journal of Pharmacy and Pharmacology, 2023, 75, 370-384.	1.2	3
252	Lupus Nephritis: Clinical Picture, Histopathological Diagnosis, and Management. , 0, , .		0
253	Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies. Pharmaceuticals, 2023, 16, 155.	1.7	6
254	Pharmacological importance of Kunxian Capsule in clinical applications and its adverse effects: A review. Chinese Herbal Medicines, 2023, 15, 222-230.	1.2	1
255	Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2023, 24, 6578.	1.8	8
256	Early and differential autoimmune diseases diagnosis by interrogating specific autoantibody signatures with multiplexed electrochemical bioplatforms. Biosensors and Bioelectronics: X, 2023, 13, 100325.	0.9	2
258	Antibodies to calnexin and mutated calreticulin are common in human sera. Current Research in Translational Medicine, 2023, 71, 103380.	1.2	1
260	Implementation effect of a hierarchical pharmaceutical service pattern in patients with systemic lupus erythematosus. Journal of International Medical Research, 2023, 51, 030006052311547.	0.4	1
261	Research Progress of Drug Therapy for Systemic Lupus Erythematosus. , 2022, , 521-527.		0
262	Systemic lupus erythematosus is associated with increased risk of Parkinsonâ€™s disease. Therapeutic Advances in Musculoskeletal Disease, 2023, 15, 1759720X2311526.	1.2	0
263	Complement as a Biomarker for Systemic Lupus Erythematosus. Biomolecules, 2023, 13, 367.	1.8	8
264	Effects of DNA Immunoadsorption Combined with Medication on Immune Function and Renal Function in Patients with Systemic Lupus Erythematosus. Journal of Environmental and Public Health, 2023, 2023, 1-7.	0.4	1
265	Application of Machine Learning Models in Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2023, 24, 4514.	1.8	5
266	Honokiol suppresses the aberrant interactions between renal resident macrophages and tubular epithelial cells in lupus nephritis through the NLRP3/IL-33/ST2 axis. Cell Death and Disease, 2023, 14, .	2.7	2
267	The circRNAâ€“miRNAâ€“mRNA regulatory network in plasma and peripheral blood mononuclear cells and the potential associations with the pathogenesis of systemic lupus erythematosus. Clinical Rheumatology, 2023, 42, 1885-1896.	1.0	2
268	Cytotoxic CD161â^'CD8+ TEMRA cells contribute to the pathogenesis of systemic lupus erythematosus. EBioMedicine, 2023, 90, 104507.	2.7	7

#	Article	IF	Citations
269	The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus. Frontiers in Immunology, 0, 14, .	2.2	3
270	Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses. Frontiers in Immunology, 0, 14, .	2.2	5
271	Integrated analysis and clinical correlation analysis of hub genes, immune infiltration, and potential therapeutic agents related to lupus nephritis. Lupus, 0, , 096120332311615.	0.8	0
272	Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). CKJ: Clinical Kidney Journal, 0, , .	1.4	0
273	Low P-Selectin Glycoprotein Ligand-1 Expression in Neutrophils Associates with Disease Activity and Deregulated NET Formation in Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2023, 24, 6144.	1.8	1
274	CARD19, a Novel Regulator of the TAK1/NF-Î²B Pathway in Self-Reactive B Cells. Journal of Immunology, 2023, 210, 1222-1235.	0.4	0
275	Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. Rheumatology, 2023, 62, i22-i29.	0.9	9
277	Identification of NETs-related biomarkers and molecular clusters in systemic lupus erythematosus. Frontiers in Immunology, 0, 14, .	2.2	23
278	Delivery of AntagomiR-7 through polymer nanoparticles for assisting B Cell to alleviate systemic lupus erythematosus. Frontiers in Bioengineering and Biotechnology, 0, 11, .	2.0	3
279	Megamonas funiformis, Plasma Zonulin, and Sodium Intake Affect C3 Complement Levels in Inactive Systemic Lupus Erythematosus. Nutrients, 2023, 15, 1999.	1.7	5
282	Overview of microbial therapeutics in immunological disorders. , 2023, , 289-353.		1
288	Non-coding RNAs in human non-infectious diseases. , 2023, , 273-319.		0
305	Diverse functions of myeloid-derived suppressor cells in autoimmune diseases. Immunologic Research, 0, , .	1.3	0
306	Atherosclerosis in Systemic Lupus Erythematosus. Current Atherosclerosis Reports, 2023, 25, 819-827.	2.0	2
308	Diagnostic challenge of tuberculosis in systemic lupus erythematosus: a case report and literature review. Rheumatology International, 2023, 43, 2131-2139.	1.5	1
352	Herbs for Autoimmune Diseases. , 2023, , 361-388.		0